Myocardial infarction in an adolescent taking Adderall

American Journal of Health-System Pharmacy

Volumn 62, Issue 14, 2005, Pages 1494-1497

  Gandhi, Pritesh J ^a,b   Ezeala, Gladys U ^c   Luyen, Tuonglan T ^d   Tu, Tran C ^e,f   Tran, Maichi T ^e,f,g  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

^c CVS Caremark   (United States)

^d Walgreen's Pharmacy   (United States)

^e Cardiovascular/Anticoagulation Fellowship   (United States)

^f UMMHC   (United States)

^g UMASS MEMORIAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMPHETAMINE; AMPHETAMINE DERIVATIVE; DILTIAZEM; EPTIFIBATIDE; HEPARIN; LORAZEPAM; PANTOPRAZOLE;

ADOLESCENT; ANGIOCARDIOGRAPHY; ATTENTION DEFICIT DISORDER; CASE REPORT; CLINICAL FEATURE; ELECTROCARDIOGRAM; EMERGENCY WARD; ENTERIC COATED TABLET; HEART CATHETERIZATION; HEART INFARCTION; HUMAN; INTENSIVE CARE UNIT; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REVIEW; ST SEGMENT ELEVATION; TREATMENT WITHDRAWAL;

EID: 22444433119     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp040220     Document Type: Review

References (24)

1. Pliszka SR. The use of psychostimulants in the pediatric patient. Pediatr Clin North Am. 1998; 45:1085-98.
2. National Institute on Drug Abuse. Research report series: methamphetamine abuse and addiction, www.nida.nih.gov/ PDF/RRMetham.pdf (accessed 2005 Mar 30).
3. Karch S. The problem of methamphetamine toxicity. West J Med. 1999; 170: 232. Editorial.
4. Hoffman BB. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Limbird LE, Molinoff PB et al., eds. Goodman and Gilman's the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill; 2001:224-35.
5. Derlet RW, Albertson TE, Rice P. The effect of haloperidol in cocaine and amphetamine intoxication. J Emerg Med. 1989; 7:633-7.
6. Richards CF, Clark RF, Holbrook T et al. The effect of cocaine and amphetamines on vital signs in trauma patients. J Emerg Med. 1995; 13:59-63.
7. Sztajnkrycer MD, Hariharan S, Bond R. Cardiac irritability and myocardial infarction in a 13-year-old girl following recreational amphetamine overdose. Pediatr Emerg Care. 2002; 18(4):E11-5.
8. Qasim A , Townend J, Davies MK. Ecstasy induced acute myocardial infarction. Heart. 2001; 85:E10.
9. Lai TI, Hwang JJ, Fang CC et al. Methylene 3,4 dioxymethamphetamine- induced acute myocardial infarction. Ann Intern Med. 2003; 42:759-62.
10. Waksman J, Taylor RN Jr, Bodor GS et al. Acute myocardial infarction associated with amphetamine use. Mayo Clin Proc. 2001; 76:323-6.
11. Costa GM, Pizzi C, Bresdani B et al. Acute myocardial infarction caused by amphetamines: a case report and review of the literature. Ital Heart J. 2001; 2:478-80.
12. Ragland AS, Ismail Y, Arsura EL. Myocardial infarction after amphetamine use. Am Heart J. 1993; 125:247-9.
13. Packe GE, Garton MJ, Jennings K. Acute myocardial infarction caused by intravenous amphetamine abuse. Br Heart J. 1990; 64:23-4.
14. Bashour TT. Acute myocardial infarction resulting from amphetamine abuse: a spasm-thrombus interplay? Am Heart J. 1994; 128:1237-9.
15. Carson P, Oldroyd K, Phadke K. Myocardial infarction due to amphetamine. Br Med J (Clin Res Ed). 1987; 294:1525-6.
16. Ahmann PA, Theye FW, Berg R et al. Placebo-controlled evaluation of amphetamine mixture-dextroamphetamine salts and amphetamine salts (Adderall): efficacy rate and side effects. Pediatrics. 2001; 107:E10.
17. Food and Drug Administration. Public health advisory for Adderall and Adderall XR. www.fda.gov/cder/drug/advisory/ adderall.htm (accessed 2005 Feb 16).
18. Food and Drug Administration. Alert for health care professionals. Adderall and Adderall XR (amphetamine). www. fda.gov/cder/drug/InfoSheets/HCP/ AdderallHCPSheet.pdf (accessed 2005 Feb 16).
19. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30:239-45.
20. Michelson D, Allen AJ, Busner J et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002; 159:1896-901.
21. Wernicke JF, Kratochvil CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry. 2002; 63(suppl 12):50-5.
22. Goldman LS, Genel M, Bezman RJ et al. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. JAMA. 1998; 279:1100-7.
23. Spencer T, Biederman J, Wilens T et al. Pharmacotherapy of attention-deficit/ hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry. 1996; 35:409-32.
24. Pliszka SR, Greenhill LL, Crismon ML et al. The Texas Children's Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Attention-Deficit/Hyperactivity Disorder. Parts I and II. J Am Acad Child Adolesc Psychiatry. 2000; 39:908-27.